Introduction {#S1}
============

Schizophrenia is a multifaceted syndrome characterized by distinctive behavioral symptoms, cognitive deficits, and a complex etiopathogenesis, which seems to involve neurodevelopmental anomalies and a combination of genetic and environmental factors ([@B1], [@B2]). Among the environmental factors, *Toxoplasma gondii* (*T. gondii*) is gaining increasing attention, and a causal association between the protozoan infection and schizophrenia has been repeatedly suggested ([@B3]--[@B9]). Over the last decades, studies on *T. gondii* antibodies (Abs) in patients with schizophrenia revealed higher levels of anti-*T. gondii* Abs in the affected persons when compared to controls ([@B8], [@B10]--[@B12]). Interestingly, higher anti-*T. gondii* Ab levels were also found in mothers of offspring who later developed schizophrenia ([@B13]) and in newborns who later were diagnosed with the disease, as compared to controls ([@B6], [@B14]). This suggests that toxoplasmosis in early life might affect neurodevelopment and contribute to later onset of schizophrenia. However, the molecular determinants and mechanisms by which *T. gondii* infection might contribute to the pathophysiology of the disease remain unclear.

One major pathophysiological mechanism underlying development of schizophrenia seems to be *N*-methyl-[d]{.smallcaps}-aspartate glutamate receptor (NMDAR) dysfunction ([@B15]--[@B17]). The NMDA model of schizophrenia originated from the observation that NMDA antagonists, like ketamine or phencyclidine (PCP), transiently induce symptoms that mimic psychotic episodes ([@B18]--[@B21]). Following these initial observations, a large body of genetic and molecular evidence has accumulated in the last three decades indicating NMDA dysfunction as a convergence point in the development of schizophrenia ([@B22]--[@B27]). NMDA dysfunction not only can provide a satisfactory explanation of behavioral and cognitive symptoms of schizophrenia but is also consistent with the neurodevelopmental aspect of the disease, given that early NMDA aberrations/damage can translate into clinical onset later in life ([@B22], [@B28], [@B29]).

In summary, the NMDA model of schizophrenia seems then to be the common pathway of different etiological factors and is characterized by an early-damage late-onset temporal pattern, which is consistent with findings on increased risk of schizophrenia after early-life *T. gondii* infection. It is therefore reasonable to hypothesize that *T. gondii* can affect NMDAR function and glutamatergic neuronal circuits.

On this basis, the present work examines the hypothesis that immune responses to *T. gondii* may relate to NMDAR dysfunction by way of cross-reactive mechanisms and anti-NMDAR Abs. The rationale is that when a pathogen has sequence/structure similarity with human proteins, then anti-pathogen immune responses may cross-react with human proteins that share sequences/structures with the pathogen, thus triggering autoimmunity ([@B30], [@B31]). Such a hypothesis originates form the observations that (1) anti-*T. gondii* Ab levels are, as discussed above, higher in schizophrenic patients ([@B8], [@B10]--[@B12]), thus suggesting that immune responses following *T. gondii* active infection might play a role in the association of the parasite with the disease and (2) NMDAR blocking Abs are present in subjects with schizophrenia, schizoaffective, bipolar, and major depressive disorders ([@B32]--[@B37]), thus suggesting a role of anti-NMDAR immunoreactivity in the genesis of NMDA dysfunction in schizophrenia and other neuropsychiatric disorders. Moreover, a direct effect of early toxoplasmosis on behavioral anomalies and elevation of anti-NMDAR autoantibodies was found in a recent study on mice ([@B38]).

In light of this immunologic context, *T. gondii* proteome and the seven NMDAR subunit proteins (NMDA 1, 2A, 2B, 2C, 2D, 3A, and 3B) were searched for common peptides that might underlie immune cross-reactions between the protozoan and the human host. Data are reported showing that the *T. gondii* proteome and NMDAR subunits share a vast epitopic peptide platform that is centered on the 2D subunit and appears to be potentially significant to schizophrenia pathogenesis.

Methods {#S2}
=======

The seven human NMDAR subunit aminoacidic sequence analyzed in this study were retrieved from the UniProt database[^1^](#fn1){ref-type="fn"} ([@B39]), and are listed with their alternative names in parentheses, followed by amino acids (aa) length: NMDA 1 (GluN1, NMDZ1), 938; NMDA 2A (GluN2A, NMDE1), 1,464; NMDA 2B (GluN2B, NMDE2), 1,484; NMDA 2C (GluN2C, NMDE3), 1,233; NMDA 2D (GluN2D, NMDE4), 1,336; NMDA 3A (GluN3A, NMD3A), 1,115; and NMDA 3B (GluN3B, NMD3B), 1,043.

The protein sequence of each NMDA subunit was dissected into sequential hexapeptides that overlapped each other by five aa (for example, MSTMRL, STMRLL, TMRLLT, MRLLTL, and so forth). This procedure produced a library consisting of 8,578 NMDAR subunit hexapeptides. Each NMDAR hexapeptide was used as a probe to search the entire *T. gondii* proteome for occurrences of the same hexapeptide using the Pir Peptide Match program[^2^](#fn2){ref-type="fn"} ([@B40]).

*Toxoplasma gondii* (strain VEG, NCBI Tax ID: 432359) was investigated. The *T. gondii* proteome consists of 8,404 proteins (Uniprot proteome: UP000002226). The protozoan *Entamoeba histolytica* (NCBI Tax ID: 5759; 7,959 proteins; Uniprot proteome: UP000001926) was used as a control.

The Immune Epitope DataBase[^3^](#fn3){ref-type="fn"} (IEDB) ([@B41]) was searched for epitopes containing (or corresponding to) NMDAR hexapeptide(s) shared with *T. gondii* and experimentally validated as immunopositive in humans. Details, references, and immunoassay type for each epitope reported in the present study are available at <http://www.iedb.org/advancedQueryEpitope.php>.

Results {#S3}
=======

Sequence-matching analyses were carried out at the 6-mer level since a grouping of 5--6 aa represents the minimal immune unit able to induce specific Abs and to determine specific antigen--antibody recognition ([@B42]--[@B44]).

The hexapeptide sharing between NMDAR subunits and *T. gondii* proteins and its immunological potential is quantified in Table [1](#T1){ref-type="table"} and detailed in Table S1 in the Supplementary Material. Table [1](#T1){ref-type="table"} shows that the seven NMDAR subunit proteins share a high number of hexapeptides with the protozoan proteome. On the whole, 2,215 out of the 8,578 hexapeptides composing the NMDAR library repeatedly occur in the protozoan proteome, for a total of 5,802 multiple occurrences. Theoretically, such an impressive level of peptide sharing equates to a vast source of potential cross-reactions in case of active toxoplasmosis and, indeed, NMDAR hexapeptides shared with the *T. gondii* proteome are also present in immunopositive epitopes (Table [1](#T1){ref-type="table"}, last column).

###### 

***N*-methyl-[d]{.smallcaps}-aspartate receptor (NMDAR) hexapeptide sharing with *Toxoplasma gondii* proteome**.

  NMDAR subunit   Total number of hexapeptides   Hexapeptides shared with *T. gondii* proteome   Hexapeptides shared with *T. gondii* proteome (including multiple occurrences)   Hexapeptides shared with *T. gondii* proteome and present in immunopositive epitopes
  --------------- ------------------------------ ----------------------------------------------- -------------------------------------------------------------------------------- --------------------------------------------------------------------------------------
  1               933                            180                                             504                                                                              10
  2A              1,459                          254                                             488                                                                              16
  2B              1,479                          258                                             400                                                                              7
  2C              1,228                          374                                             947                                                                              22
  2D              1,331                          496                                             1,463                                                                            58
  3A              1,110                          262                                             977                                                                              8
  3B              1,038                          391                                             1,023                                                                            44
                                                                                                                                                                                  
  **Total:**      8,578                          2,215                                           5,802                                                                            165

In order to define the immunologic potential of the hexapeptide commonality between NMDARs and *T. gondii*, the shared 2,215 hexapeptides were analyzed using the IEDB, an immune epitope catalog resource, in search of epitopes experimentally validated as immunopositive in the human host, and containing (or corresponding to) hexapeptides shared between *T. gondii* and human NMDAR proteins. One hundred sixty out of the 2,215 hexapeptides shared between the 7 human NMDARs and *T. gondii* were found to be disseminated through hundreds of IEDB epitopes that have been validated as immunopositive in humans. The 160 epitopic NMDAR hexapeptides and the IEDB epitopes are described in Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}, respectively.

###### 

**Epitopic hexapeptides shared between the seven human *N*-methyl-[d]{.smallcaps}-aspartate receptor (NMDAR) subunit proteins and *T. gondii* proteome and present in epitopes experimentally validated as immunopositive in humans**.^[a](#tfn1){ref-type="table-fn"},[b](#tfn2){ref-type="table-fn"}^

  NMDA 1          NMDA 2A      NMDA 2B      NMDA 2C      NMDA 2D      NMDA 3A      NMDA 3B
  --------------- ------------ ------------ ------------ ------------ ------------ ------------
  [AGGIVA]{.ul}   AAAEKG       AAPVAV       AGVSSS       AAAATA       APRAAS       AALARA
  [EEEEED]{.ul}   **ALSLIT**   **ALSLIT**   ASPPRQ       AAPPPA       **EELSGI**   AAPAEA
  [ELEARV]{.ul}   APSAAA       LAVLAV       FLDLPL       AATAVG       LLEKIA       AEAEAA
  [ELLEKE]{.ul}   EELETL       **LKTGKL**   GPALLL       AGGAGG       NFSLLL       ALLPRA
  GRGALQ          ISLKDR       LRLLRT       GPGGPR       AGGGGS       PFSSPS       ALLSSL
  LVAGGI          KGPPAL       QEAIAQ       LGPALL       APGPAP       PPGSRK       APRLPH
  RGALQN          LEARVR       QKEEAA       LLLTSL       APPAAA       SELEKQ       APVPAA
  [SPGSPR]{.ul}   **LKTGKL**                LLTSLF       APPPPP       VPSSSS       ARAAPA
  [SVARAA]{.ul}   LPALLV                    LSLRQK       APRGAA                    ARARAR
  TLASSF          LRSTAS                    **LTVATL**   APRPAP                    ARPPPP
                  RELDLS                    PALLLT       AVAAAV                    ATLDAL
                  SLEARV                    PGGPRA       AVGPPL                    EAPVPA
                  SRDSRG                    PPPSPC       AVVARG                    **EELSGI**
                  SRPSRS                    QASPDL       GAAGRP                    EGSKEE
                  SRSISL                    RSVEDA       GAALVL                    ELVVAA
                  SSVILL                    SASERP       GAGEAV                    EQQQQQ
                                            SFSPGG       GAGGAG                    ERLRQA
                                            SLASPP       GAGGGA                    GEAPVP
                                            SSVAEA       GAGGPG                    GGLVAL
                                            TAGVSS       GAPAAP                    GLALAL
                                            TDAPPA       GASLGG                    GLLALG
                                            **TVATLE**   GGAGGG                    GRPPAA
                                                         GGAGGP                    GSALLS
                                                         GGGGSG                    GVAALL
                                                         GGGLGG                    GVLARL
                                                         GGPGGG                    LARAAL
                                                         GKKIDG                    LEHPFV
                                                         GLGLGL                    LERRIE
                                                         KPPPPP                    LGSALL
                                                         LAGGGG                    LLAQLG
                                                         LELLPP                    LLQARA
                                                         LLLLAL                    LQARAA
                                                         LLSGLR                    PEADAE
                                                         LPPPAP                    PGVAAL
                                                         **LTVATL**                PPGVAA
                                                         PAAAAP                    PPPPQG
                                                         PAAAAT                    PRAPLA
                                                         PAEPPA                    PTGAPQ
                                                         PAPPAA                    QELERR
                                                         PGPGGA                    QQQQQQ
                                                         PLPSPA                    RARAAL
                                                         PPAAAA                    RARARA
                                                         PPPPPQ                    RLRQAL
                                                         PRGAAG                    VLSLLR
                                                         PSPPAP                    
                                                         PVALVL                    
                                                         RAAPPP                    
                                                         RAPAVA                    
                                                         RGAGGP                    
                                                         RGAQAL                    
                                                         RGPRGP                    
                                                         SGPAYA                    
                                                         SLELLP                    
                                                         SPPAPA                    
                                                         TPAAAA                    
                                                         **TVATLE**                
                                                         VRPVAL                    
                                                         VSAQIR                    

*^a^Hexapeptides common to the seven isoforms of NMDA 1 are given underlined*.

*^b^The five hexapeptides present in more than one subunit are in bold*.

###### 

**Immunopositive epitopes containing hexapeptides shared between the seven human *N*-methyl-[d]{.smallcaps}-aspartate receptor (NMDAR) subunit proteins and *T. gondii* proteome**.

  IEDB ID[^a^](#tfn3){ref-type="table-fn"}   Epitope[^b^](#tfn4){ref-type="table-fn"}   IEDB ID[^a^](#tfn3){ref-type="table-fn"}   Epitope[^b^](#tfn4){ref-type="table-fn"}   IEDB ID[^a^](#tfn3){ref-type="table-fn"}   Epitope[^b^](#tfn4){ref-type="table-fn"}   IEDB ID[^a^](#tfn3){ref-type="table-fn"}   Epitope[^b^](#tfn4){ref-type="table-fn"}   IEDB ID[^a^](#tfn3){ref-type="table-fn"}   Epitope[^b^](#tfn4){ref-type="table-fn"}
  ------------------------------------------ ------------------------------------------ ------------------------------------------ ------------------------------------------ ------------------------------------------ ------------------------------------------ ------------------------------------------ ------------------------------------------ ------------------------------------------ ------------------------------------------
  364                                        aapLPPPAPd                                 178516                                     ALLPRAgaaaaaalp                            243209                                     rvLRLLRTlrplrvi                            446380                                     lprALLSSL                                  460038                                     tpAVGPPL
  1432                                       aGAGGGAGGAGag                              179362                                     QASPDLlrgllstfi                            255107                                     apakaaAPPAAArsa                            446610                                     miRAAPPPl                                  460172                                     vagLAVLAV
  11210                                      eavesTVATLEd                               179712                                     ylglevltRARAALt                            260421                                     avGVAALLplptvva                            446684                                     mPPPPPQGv                                  460179                                     vAPPPPPvev
  16552                                      FLDLPL                                     180820                                     wlvhrqwFLDLPLpw                            265472                                     ddddddepeEGSKEE                            447353                                     rgsLARAAL                                  460604                                     VRPVALVL
  16553                                      FLDLPLpwl                                  189280                                     slyLTVATL                                  275388                                     edEEEEEDEEEEEDe                            447526                                     rpaLPALLV                                  460633                                     vtlasGGLVAL
  16554                                      FLDLPLpwt                                  193670                                     aLLSGLRea                                  348447                                     pakaaAPPAAArsae                            448486                                     sPGGPRAav                                  460697                                     wlknGAALVL
  19674                                      gGAGGAGGaGAGGGA                            193930                                     iiNFSLLLv                                  348613                                     papakaaAPPAAArs                            448497                                     SPGSPRpal                                  463472                                     APPPPPppv
  34978                                      laTAGVSSSdslvsp                            194050                                     kliEELETL                                  359598                                     qekkeEEEEEDgieq                            451566                                     aaaPAPPAA                                  463529                                     APRPAPvaqppaaa
  46489                                      nvsVPSSSStplly                             194088                                     klPPPPPQa                                  375698                                     sapakaaAPPAAArs                            451598                                     aaPAAAAPa                                  463617                                     APVPAAaav
  48720                                      pnvsVPSSSStplly                            196338                                     APPPPPppp                                  410921                                     vsapakaaAPPAAAr                            451603                                     aaPAPPAAA                                  465860                                     glsgSGPAYA
  51177                                      QKEEAAicgqmdls                             196592                                     KPPPPPppp                                  418132                                     fqinqdEEEEEDed                             451607                                     aAPGPAPl                                   466021                                     gpPSPPAPvm
  67823                                      vaytlaTAGVSSSds                            198666                                     AEAEAAsvrm                                 418885                                     sprrSRSISL                                 451608                                     aAPPAAAAa                                  466282                                     hlwtgevsAAPPPA
  68358                                      vesTVATLEd                                 199105                                     aeprPAEPPAw                                419522                                     apqAPPPPPk                                 451658                                     AEAEAAvgl                                  466749                                     ipLLLTSL
  69908                                      vlyspnvsVPSSSS                             202838                                     atASPPRQk                                  420032                                     pvRAPAVAv                                  452024                                     aEQQQQQmy                                  466793                                     iprgpPSPPAPv
  73319                                      yAALARAAL                                  210095                                     gLLEKIATpk                                 420626                                     kLVAGGInav                                 452378                                     ALLSSLarc                                  466794                                     iprgpPSPPAPvm
  77946                                      LGPALLLll                                  217152                                     qlkLKTGKL                                  423463                                     prppplgrgRGAGGP                            452567                                     aPAAAAPaa                                  469288                                     ppAPPPPPv
  94735                                      VPSSSStpl                                  217651                                     RELDLSgqgf                                 423802                                     AAAATAdvtly                                452663                                     apgKGPPAL                                  470036                                     rpikGAAGRPlel
  103165                                     feetfevtaAAPVAV                            219411                                     spaSRSISL                                  424158                                     avSSVAEAy                                  452666                                     APGPAPsql                                  470660                                     slmaelGEAPVPAsv
  103645                                     tgGGGGSGfsnsgsg                            222405                                     GEAPVPAsv                                  424351                                     ffGAGGAGy                                  452751                                     APPPPPkal                                  474124                                     yTDAPPAysel
  113351                                     eaGAGGGA                                   224924                                     pAPPPPPpp                                  424829                                     GASLGGiiy                                  452752                                     APPPPPtsm                                  474710                                     AEAEAAavhga
  114666                                     vrSRPSRSrssrser                            227016                                     aGAGGGAGAGGAGGa                            424842                                     gffGAGGAGy                                 452779                                     aprelGLGLGL                                474785                                     aeAPPPPPp
  115985                                     sTVATLEdsp                                 227017                                     AGAGGGAGAGGGAgg                            426558                                     nlLQARAAlqtay                              452781                                     APRGAAGl                                   475138                                     aelGEAPVP
  118616                                     svsyddwdySLEARV                            227018                                     AGAGGGAGGAGaggg                            427326                                     SLELLPPp                                   452792                                     APRPAPvaq                                  475252                                     aeqepELEARVa
  121117                                     adGKKIDG                                   227019                                     aGAGGGAGGAGGaga                            433554                                     yTDAPPAysely                               452810                                     APSAAAlpa                                  476614                                     avrPPAAAAak
  121776                                     RARARARa                                   227020                                     AGAGGGAGGAGGagg                            435140                                     grlPLPSPAl                                 453128                                     dqvgGVLARL                                 477189                                     eaPAAAATA
  121811                                     rRARARAR                                   227021                                     aggaGAGGAGaggag                            435175                                     grSSVILLty                                 454126                                     gLAVLAVvv                                  477192                                     eAPPPPPpp
  122052                                     ykhadGKKIDGrrvl                            227023                                     aggaGAGGGAgagga                            435395                                     krQEAIAQnr                                 454159                                     GLLALGdymnv                                477741                                     eLGSALLSl
  127989                                     ggaGAGGGAgagg                              227024                                     aggaGAGGGAGGAGG                            437234                                     fELLEKEvgl                                 454273                                     GPGGPRnl                                   479011                                     gveGAPAAP
  132330                                     GGGLGGtrrg                                 227025                                     aggGAGGAGAGGGAg                            437708                                     gPPPPPQGgrpp                               454675                                     ikGAAGRPlel                                482100                                     lqkLKTGKL
  132548                                     prrlGGGLGG                                 227188                                     gaGAGGGAGGAGagg                            437719                                     gptslgGGAGGPll                             455937                                     lAAPPPApa                                  482881                                     paaAPPAAA
  132613                                     rlGGGLGGtr                                 227189                                     GAGGAGAGGGAGGAG                            438549                                     kEQQQQQmw                                  455970                                     lAPPPPPaa                                  483053                                     qeAPPPPPp
  138044                                     SRDSRGkpgy                                 227204                                     ggGAGGAGAGGGAgg                            438691                                     klqELEARV                                  456697                                     lsrlPALLLTg                                486281                                     spaSRSISLl
  142502                                     aAGGGGStdnlsy                              235218                                     lGVAALLfgfpiffd                            439841                                     refPEADAEkl                                457321                                     paAAAATAl                                  487382                                     tevAPPPPP
  144908                                     iepRGAQAL                                  236707                                     aeLRSTASll                                 440445                                     SELEKQdnsw                                 457322                                     PAAAAPaaa                                  492366                                     iRAAPPPlfll
  146892                                     epeAEAEAAagpgp                             239263                                     AATAVGggflll                               441412                                     vLLAQLGpqpg                                457324                                     paaPAAAAPgy                                492772                                     krGLALALf
  150802                                     iRAAPPPlf                                  239392                                     alLAGGGGppak                               442395                                     amPPPPPQGv                                 457338                                     papARAAPA                                  493404                                     mrpGPALLLlgv
  156427                                     qqgrQQQQQQQgqqg                            239445                                     aprelglGLGLGL                              442558                                     appERLRQAL                                 457425                                     PPGVAALsi                                  495305                                     srTPAAAAam
  161826                                     aegGRPPAA                                  239460                                     aprpaAAAATAl                               442568                                     APRAAStesl                                 457922                                     rARPPPPstl                                 504497                                     APGPAPtrc
  162831                                     LEHPFVssi                                  239463                                     APRPAPvaqppa                               442615                                     APRLPHsvtc                                 458285                                     rpaGPALLL                                  504498                                     APGPAPtrcl
  169260                                     maiakaAAAEKGvpl                            239473                                     aprtPGPGGArl                               442702                                     apsSPGSPRpal                               458546                                     rpyLGPALL                                  505654                                     gpgifPPPPPQp
  176712                                     VSAQIRknf                                  239607                                     eestgLLSGLRiw                              443010                                     AVVARGttilak                               458547                                     rpyLGPALLL                                 505667                                     gPPPPQGkp
  176870                                     AEAEAAavhgarf                              240452                                     SPPAPAgsratl                               444271                                     glaAGGIVAv                                 458577                                     RSVEDAqaw                                  507174                                     miRAAPPPlf
  176959                                     agytpatpAAPAEAa                            240535                                     stAPPPPPllle                               444325                                     gLVAGGIiga                                 459541                                     sprpaLPALLV                                507502                                     pgaRGPRGPp
  177000                                     eaqkaakPAAAATAt                            240571                                     tgggGGGGSGgtrm                             444514                                     grlPLPSPAley                               459542                                     sprPFSSPSm                                 507608                                     qgPPPPQGkpq
  177124                                     kaakPAAAATAtata                            240573                                     tkeAVAAAVaav                               445222                                     iRAAPPPlfl                                 459704                                     sTLASSFk                                   509894                                     LPPPAPaev
  177139                                     kPAAAATAtataavg                            242669                                     ilgmlrvLRLLRTlr                            446022                                     ktlLLTSLF                                  459875                                     tgAPGPAPp                                  510025                                     ndAPRAASi

*^a^Immunopositive epitopes containing hexapeptides shared between T. gondii and NMDAR subunits are listed according to IEDB ID number. Only epitopes ≤15 aa are reported. Details and references are available at [www.immuneepitope.org/](www.immuneepitope.org/)*.

*^b^Peptide sequences shared between NMDAR subunit proteins and T. gondii proteome are given in capital letters*.

Control analyses using the protozoan *E. histolytica*, a human pathogen associated with intestinal and extraintestinal infections ([@B45]), highlight a lower extent of peptide sharing (Table [4](#T4){ref-type="table"}), thus indicating that the intensity of the hexapeptide sharing between *T. gondii* and the NMDAR subunits---in particular, NMDA 2D and 3B---is specific (Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}). The detailed description of the peptide sharing between the NMDAR subunits and the protozoan *E. histolytica* is reported in Tables S2 and S3 in Supplementary Material.

###### 

***N*-methyl-[d]{.smallcaps}-aspartate receptor (NMDAR) hexapeptide sharing with *Entamoeba histolytica* proteome**.

  NMDAR subunit   Total number of hexapeptides   Hexapeptides shared with *E. histolytica* proteome   Hexapeptides shared with *E. histolytica* proteome (including multiple occurrences)   Hexapeptides shared with *E. histolytica* proteome and present in immunopositive epitopes
  --------------- ------------------------------ ---------------------------------------------------- ------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------
  1               933                            100                                                  240                                                                                   13
  2A              1,459                          134                                                  227                                                                                   10
  2B              1,479                          160                                                  241                                                                                   9
  2C              1,228                          92                                                   141                                                                                   5
  2D              1,331                          109                                                  192                                                                                   15
  3A              1,110                          101                                                  211                                                                                   3
  3B              1,038                          86                                                   142                                                                                   10
                                                                                                                                                                                            
  **Total:**      8,578                          782                                                  1,394                                                                                 65

Discussion {#S4}
==========

The Spatiotemporal NMDAR Subunit Expression May Shape the Potential Cross-reactions between *T. gondii* and NMDARs {#S4-1}
------------------------------------------------------------------------------------------------------------------

Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"} indicate that *T. gondii* active infection might induce immune reactions able to cross-react to different extents with the seven NMDAR subunits. In particular, analysis of Table [2](#T2){ref-type="table"} shows that epitopic hexapeptides shared with *T. gondii* are mostly allocated in the NMDA 2D, 3B, and 2C subunits (58, 44, and 22 epitopic hexapeptides, respectively), whereas a relatively lower level of hexapeptide sharing characterizes NMDA 2A, 1, 3B, and 3A (16, 10, 8, and 7 epitopic hexapeptides, respectively).

This appears to be relevant in light of the fact that NMDARs consist of four subunits, two of which invariably are NMDA 1 subunits that can associate with NMDA 2 subunits or a combination of NMDA 2 and NMDA 3 subunits. Such a variable composition results in a large number of NMDAR subtypes, which present different spatiotemporal patterns of expression during neurodevelopment and in the young/adult life ([@B46]). For instance, NMDA 2B and NMDA 2D are expressed during embryonic development, whereas NMDA 2A and NMDA 2C gene expression starts after birth; NMDA 2A and NMDA 2B are highly expressed in the cortex and hippocampus and NMDA 2C in the cerebellum of adult rodents ([@B47]--[@B52]). Likewise, NMDA 3A and NMDA 3B genes have specific developmental patterns of expression ([@B53]).

Even the NMDA 1 subunit, which is a constitutive component of all NMDARs, presents a heterogenous distribution and a varying immunoreactivity potential when its seven isoforms are analyzed ([@B54]). For example, only immune cross-reactions against 6 out of the 10 epitopic hexapeptides present in all NMDA 1 isoforms (Table [2](#T2){ref-type="table"})---namely, AGGIVA, EEEEED, ELEARV, ELLEKE, SPGSPR, and SVARAA---should be able to produce a diffuse immunoreactivity in the brain.

Hence, *T. gondii*-induced immune cross-reactions might have different outcomes depending on the targeted NMDAR subunit and might target different subunits depending on the timing of exposure to the protozoan. Indeed, the timing of exposure to *T. gondii* is a crucial factor in generating different specific anti-NMDAR Abs and, consequently, different associated neurobehavioral disorders ([@B38]).

NMDA 2D Is the Main Potential Target of Anti-*T. gondii* Immune Response {#S4-2}
------------------------------------------------------------------------

NMDA 2D exemplifies the potential relationship between toxoplasmosis-induced immunoreactivity, the spatiotemporal expression profile of NMDAR subunits, and different potential outcomes. Indeed, NMDA 2D contains 496 hexapeptides in common with the protozoan (Table [1](#T1){ref-type="table"}), 58 of which are present in validated immunopositive epitopes (Table [1](#T1){ref-type="table"}). Therefore, NMDA 2D might be the main target of the immune cross-reactivity potentially associated with *T. gondii* infection. Studies in animals \[([@B48]--[@B52]) and more references therein\] showed that NMDA 2D gene expression: --is high in the midbrain, the diencephalon, and the spinal cord before birth;--is abundant around birth in thalamic and hypothalamic nuclei and in the brainstem;--reaches a peak around 1 week after birth; and--subsequently declines and persists mainly in the hippocampal interneurons, most of which are somatostatin (SOM)- and parvalbumin (PV)-positive cells.

Translating data from animal models to the human brain, it is logical to presume that immune cross-reactions involving NMDA 2D in the fetus and the newborn can extensively occur throughout the brain, whereas secondary immune responses after early sensitivization might target hippocampal PV- and SOM-positive interneurons in the young/adult. Indeed, alterations in the hippocampal PV- and SOM-positive interneurons have been repeatedly related to the hippocampal hyperactivity that characterizes schizophrenia ([@B55]--[@B57]).

NMDARs vs *T. gondii* Epitopic Peptide Overlap and the NMDA Model of Schizophrenia {#S4-3}
----------------------------------------------------------------------------------

The vast epitopic peptide sharing between *T. gondii* and the seven NMDAR subunits (see Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}) suggests that anti-*T. gondii* immune responses cross-reacting with NMDARs might lead to NMDAR damage and dysfunction, targeting in particular interneurons expressing NMDA 2D. Crucially, this hypothesis, which links mechanistically toxoplasmosis and schizophrenia by way of peptide sharing with NMDARs, is consistent with the well-established NMDA dys/hypofunction model of schizophrenia ([@B15]--[@B17]). As mentioned in the [Introduction](#S1){ref-type="sec"}, the NMDA model is based on the observation that NMDA antagonists, like PCP, Ketamine, and MK801, induce symptoms that resemble schizophrenia ([@B2], [@B17]), and it seems to be able to provide a good account of some aspects of the complex symptomatology of the disease, including cognitive symptoms ([@B17]). Remarkably, both of these two fundamental aspects of the NMDA model are related to the NMDA 2D subunit type. First, targeting NMDA 2D appears to be a major mechanism in the pharmacodynamics of MK801 ([@B58]), ketamine ([@B59], [@B60]), and PCP ([@B61], [@B62]). Second, 2D-containing NMDARs are typically expressed in GABAergic interneurons, where they largely contribute to excitatory post-synaptic potentials ([@B49], [@B51], [@B63]). Consequently, NMDAR dysfunction in these cells would translate into reduced GABAergic activity and consequent reduced inhibitory control of pyramidal cell activity ([@B2], [@B64]). The excitatory--inhibitory balance in cortical networks is crucial for generating high-frequency (gamma) oscillatory activity ([@B65], [@B66]), and it appears that the disruption of gamma-band oscillations (GBOs) might indeed underlie cognitive deficits in schizophrenia ([@B67]--[@B70]). On the one hand, GBOs are well known to be physiologically related to higher cognitive functions ([@B71]--[@B74]), on the other hand, they are typically altered in schizophrenic patients ([@B75]--[@B77]). Moreover, ketamine alters gamma oscillatory activity by targeting NMDA 2D ([@B59]). It appears then that NMDA 2D damage can be directly related to cognitive deficits in schizophrenia.

In summary, in the complex and articulated picture that connects PV interneurons, brain oscillation, and cognition \[Ref. ([@B78], [@B79]) for review\], a large body of evidence from pharmacological, genetic, electrophysiological, and clinical research converges on a critical role of NMDA 2D in cognition within the context of the NMDA model of schizophrenia. It is likely then that *T. gondii*-induced anti-NMDA 2D cross-reactivity might, among other different mechanisms triggered by both genetic and environmental factors, play a role in contributing to NMDA dysfunction and GABA hypofunction, thus resulting in cortical circuitry disequilibrium and, potentially, in disruption of brain oscillation and cognitive processes.

Conclusion {#S5}
==========

This work presents and examines the hypothesis that the relationship between *T. gondii* and schizophrenia might be explained by way of shared peptides (as molecular determinants) and immune cross-reactivity (as biological mechanism) between *T. gondii* proteins and the NMDAR subunits. The high and specific peptide commonality with the NMDARs shown by *T. gondii*, as compared to the control, supports the possibility that the infection might induce anti-NMDAR immune responses in the human host through cross-reactivity (Table [1](#T1){ref-type="table"}) and more so in light of the epitopic nature of many of the shared peptides (Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}). Such a hypothesis is consistent, on the one hand, with previous studies describing the potential neuropsychiatric relevance of the vast peptide commonality existing between infectious agents and the human host ([@B80]--[@B82]) and, on the other hand, with the well-established NMDA dysfunction model of schizophrenia. Hence, a possible scenario unfolds, where the differential spatiotemporal patterns of expression of the NMDAR subunits might generate the diversity of neuropathological outcomes. In this regard, immune attacks on NMDA 2D, a main potential target of *T. gondii*-induced cross-reactions, may represent a mechanistic link between *T. gondii* infection and NMDAR dysfunction in neuropsychiatric disorders.

In summary, immune cross-reactions with NMDARs following *T. gondii* infection might be one of the factors contributing to the pathophysiology of schizophrenia and associated disorders, and NMDAR subunit composition could relate to the timing and the targets of the neuropathologic sequela of the exposure to *T. gondii*. The hypothesis presented here might help to address aspects of the complex and multifactorial etiopathogenesis of schizophrenia in future clinical and basic research.
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